Altogether, these data are relevant for differential therapeutic strategies and suggest a new approach of selecting therapeutic kinase inhibitors for the two B‐CLL subsets that could be easily distinguished by the ZAP70 mRNA expression. Here, ZAP70 is linked to B-cell chronic lymphocytic leukemia.